Company Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms.
It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017.
GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
| Country | United States |
| Founded | 1965 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Michael Breen |
Contact Details
Address: 315 Montgomery Street, 10th Floor San Francisco, California 94104 United States | |
| Phone | 415 919 4040 |
| Website | gtbiopharma.com |
Stock Details
| Ticker Symbol | GTBP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000109657 |
| CUSIP Number | 36254L209 |
| ISIN Number | US36254L3087 |
| Employer ID | 94-1620407 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Martin Breen L.L.B. | President, Chief Executive Officer and Executive Chairman |
| Alan Louis Urban CPA | Chief Financial Officer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2026 | 10-Q/A | [Amend] Quarterly report |
| Mar 6, 2026 | 10-Q/A | [Amend] Quarterly report |
| Mar 2, 2026 | 10-K | Annual Report |
| Mar 2, 2026 | 8-K | Current Report |
| Jan 30, 2026 | EFFECT | Notice of Effectiveness |
| Jan 30, 2026 | 424B3 | Prospectus |
| Jan 21, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jan 8, 2026 | 424B3 | Prospectus |
| Dec 2, 2025 | EFFECT | Notice of Effectiveness |
| Dec 2, 2025 | 424B3 | Prospectus |